Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation

被引:12
作者
Eiermann, TH
Freitag, S
Cortes-Dericks, L
Sahm, H
Zander, AR
机构
[1] Univ Hamburg, Hosp Eppendorf, Dept Transfus Med, D-20246 Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Bone Marrow Transplantat Ctr, D-20246 Hamburg, Germany
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2001年 / 10卷 / 03期
关键词
D O I
10.1089/152581601750288984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rabbit anti-thymocyte globulin (ATG-Fresenius) is a polyclonal anti-serum raised against the lymphoblastic T cell line Jurkat. It is used for in vivo depletion of host and donor T cells for allogeneic stem cell transplantation. After administration of 90 mg/kg prior to transplant, rabbit immunoglobulin G (IgG) remains present for 4-5 weeks, but it is unknown how long T cell-reactive antibodies persist. Therefore, we measured anti-Jurkat antibodies by flow cytometry. The detection limit for Jurkat-reactive antibodies was 0.1 mg/ml rabbit IgG; half-maximal labeling of Jurkat cells required 183 mug/ml rabbit ATG. The mean half-life of Jurkat-reactive antibodies in 7 patients was 4 days. Detectable levels persisted up to 3 weeks with antibody levels equivalent to 0.2-4.1 mug/ml rabbit ATG. Jurkat-reactive antibodies were eliminated two-fold faster than rabbit IgG, as assessed by enzyme-linked immunosorbent assay (ELISA). The results suggest that in patients pretreated with ATG before transplantation, residual anti T-cell antibodies may effectively modulate recovery of T cells generated after transplantation, thereby lowering the incidence of severe GVHD.
引用
收藏
页码:385 / 390
页数:6
相关论文
共 7 条
[1]   ANTIBODIES AGAINST FUNCTIONAL LEUKOCYTE SURFACE MOLECULES IN POLYCLONAL ANTILYMPHOCYTE AND ANTITHYMOCYTE GLOBULINS [J].
BONNEFOYBERARD, N ;
VINCENT, C ;
REVILLARD, JP .
TRANSPLANTATION, 1991, 51 (03) :669-673
[2]   COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE ANTILYMPHOBLAST GLOBULIN ANTI-CD ANTIGEN-ANALYSIS BY FLOW-CYTOMETRY [J].
BOURDAGE, JS ;
HAMLIN, DM .
TRANSPLANTATION, 1995, 59 (08) :1194-1200
[3]   The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia [J].
Byrne, JL ;
Stainer, C ;
Cull, G ;
Haynes, AP ;
Bessell, EM ;
Hale, G ;
Waldmann, H ;
Russell, NH .
BONE MARROW TRANSPLANTATION, 2000, 25 (04) :411-417
[4]   Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients [J].
Eiermann, TH ;
Lambrecht, P ;
Zander, AR .
BONE MARROW TRANSPLANTATION, 1999, 23 (08) :779-781
[5]   Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins [J].
Genestier, L ;
Fournel, S ;
Flacher, M ;
Assossou, O ;
Revillard, JP ;
Bonnefoy-Berard, N .
BLOOD, 1998, 91 (07) :2360-2368
[6]   Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation [J].
Remberger, M ;
Svahn, BM ;
Hentschke, P ;
Löfgren, C ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 1999, 24 (08) :823-830
[7]   Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow [J].
Zander, AR ;
Zabelina, T ;
Kröger, N ;
Renges, H ;
Krüger, W ;
Löliger, C ;
Dürken, M ;
Stockschläder, M ;
de Wit, M ;
Wacker-Backhaus, G ;
Bielack, S ;
Jaburg, N ;
Rüssmann, B ;
Erttmann, R ;
Kabisch, H .
BONE MARROW TRANSPLANTATION, 1999, 23 (09) :889-893